Huh, Warner K <br/><br/>
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.  [electronic resource] 

 -  Gynecologic oncology  May 2010 
 - 248-54 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2010.01.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Benzamides<br/>Carcinosarcoma--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Imatinib Mesylate<br/>Immunohistochemistry<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Piperazines--adverse effects<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Proto-Oncogene Proteins c-kit--biosynthesis<br/>Pyrimidines--adverse effects<br/>Receptor, Platelet-Derived Growth Factor beta--biosynthesis<br/>Treatment Outcome<br/>Uterine Neoplasms--drug therapy